Werewolf Therapeutics Inc (HOWL)vsNovartis AG ADR (NVS)
HOWL
Werewolf Therapeutics Inc
$1.07
+1.90%
HEALTHCARE · Cap: $47.93M
NVS
Novartis AG ADR
$159.26
+3.59%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 273062% more annual revenue ($57.36B vs $21.00M). NVS leads profitability with a 17.5% profit margin vs -164.8%. NVS earns a higher WallStSmart Score of 48/100 (D+).
HOWL
Avoid31
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+85.7%
Fair Value
$4.68
Current Price
$1.07
$3.61 discount
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$159.26
$63.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 40.6%
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -461.1% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HOWL
The strongest argument for HOWL centers on Operating Margin.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : HOWL
The primary concerns for HOWL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
HOWL profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
HOWL carries more volatility with a beta of 0.51 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 31/100), backed by strong 17.5% margins. HOWL offers better value entry with a 85.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Werewolf Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?